natgillin/translations-raw huggingface dataset:
Marketing authorisation holder Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley Surrey, GU16 7SR United Kingdom
Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley Surrey, GU16 7SR Velika Britanija
26 Rue de la Chapelle F-68330 Huningue France
26 Rue de la Chapelle F- 68330 Huningue Francija
Tablets are round, beige to brown, non-divisible and with imprints “ NA ” on one side and “ AK” on the other side.
Tablete so okrogle, bež do rjave barve, nedeljive in z vtisnima oznakama » NA « na eni in » AK « na drugi strani.
Do not use together with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, medicines commonly used in the treatment of pain, inflammation and allergies.
Ne uporabite sočasno z drugimi nesteroidnimi antirevmatičnimi zdravili (NSAR) ali kortikosteroidi, zdravili, ki se pogosto uporabljajo pri zdravljenju bolečine, vnetja in alergij.
Do not use in case of hypersensitivity to robenacoxib or to any of the constituents of the tablets.
Ne uporabite v primeru preobčutljivosti na robenakoksib ali na katerokoli sestavino v tabletah.
Do not use in pregnant, lactating or cats used for breeding because the safety of this product has not been established in these animals.
Ne uporabite pri mačkah v obdobju brejosti, laktacije ali pri mačkah, namenjenih za razplod, ker varnost robenakoksiba pri teh živalih ni bila ugotovljena.
ADVERSE REACTIONS*
NEŽELENI UČINKI *
Administer once daily at the same time every day, for up to 6 days according to the table below.
Dajte enkrat dnevno, vsak dan ob istem času, do 6 dni glede na spodnjo tabelo.
Body weight (kg) 2.5 to less than 6 6 to less than 12
Telesna masa (kg) 2, 5 do manj kot 6 6 do manj kot 12
The tablets should not be divided or broken.
Tablete ne smejo biti deljene ali lomljene.
Do not use after the expiry date stated on the blister after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na pretisnem omotu.
The safety of this veterinary medicinal product has not been established in cats weighing less than 2.5 kg or under 4 months of age.
Varnost tega zdravila ni bila dokazana za mačke, lažje od 2, 5 kg telesne mase oziroma mlajše od 4 mesecev.
Use this veterinary medicinal product under strict veterinary monitoring in cats at risk of stomach ulcer or if the animal previously displayed intolerance to other NSAIDs.
Pri mačkah s tveganjem za razjedo na želodcu oziroma pri živalih z znano preobčutljivostjo na druge NSAR uporabite to zdravilo pod strogim veterinarskim nadzorom.
Pre-treatment with other anti- inflammatory medicines may result in additional or increased adverse effects and a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Predhodno zdravljenje z drugimi antirevmatičnimi zdravili lahko povzroči dodatne ali povečane neželene učinke, zato je potrebno pred pričetkom zdravljenja z Onsiorjem opazovati obdobje brez zdravljenja s takšnimi snovmi vsaj 24 ur.
For the person administering the veterinary medicinal product to animals
Za osebe, ki dajejo zdravilo živalim:
Wash hands after use of the veterinary medicinal product.
Po uporabi zdravila za uporabo v veterinarski medicini si umijte roke.
In small children, accidental ingestion increases the risk for NSAID adverse effects.
Pri majhnih otrocih nenamerno zaužitje poveča tveganje za neželene učinke NSAR.
For pregnant women, particularly near term pregnant women, prolonged dermal exposure may increase the risk to the foetus.
Dolgotrajnejši kontakt s kožo nosečnice, zlasti blizu porodnega termina, poveča tveganje za plod.
Onsior tablets for cats are available in cardboard boxes containing 1, 2 or 10 blisters.
Onsior tablete za mačke so na voljo v kartonskih škatlah, v katerih je 1, 2 ali 10 pretisnih omotov.
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID).
Robenakoksib je nesteroidno antirevmatično zdravilo (NSAR).
It selectively inhibits the cyclooxygenase 2 enzyme (COX-2), which is responsible for pain, inflammation or fever.
Selektivno zavira encim ciklooksigenazo 2 (COX- 2), ki je odgovoren za bolečino, vnetje ali povišano telesno temperaturo.
The cyclooxygenase 1 enzyme (COX-1) which has protective functions, e. g. in the digestive tract and kidneys, is not inhibited by robenacoxib.
Encima ciklooksigenaze 1 (COX- 1), ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah, robenakoksib ne zavira.
This product reduced pain and inflammation associated with musculoskeletal disorders in clinical trials in cats.
To zdravilo je v kliničnih poskusih na mačkah zmanjšalo bolečino in vnetje v povezavi z mišičnoskeletnimi obolenji.
45 PACKAGE LEAFLET FOR:
45 NAVODILO ZA UPORABO ZA:
Marketing authorisation holder Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley, Surrey, GU16 7SR United Kingdom
Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley, Surrey, GU16 7SR Velika Britanija
Each tablet contains the following amount of robenacoxib and bears the imprint “ NA” on one side and the following imprint on the other side:
Vsaka tableta vsebuje naslednje količine robenakoksiba in nosi vtisnjeno oznako » NA « na eni strani in naslednje vtisnjene oznake na drugi strani:
Robenacoxib/ tablet 5 mg 10 mg 20 mg 40 mg
Robenakoksib/ tableta 5 mg 10 mg 20 mg 40 mg
Imprints AK BE CD BCK
Vtisnjene oznake AK BE CD BCK
Onsior tablets are flavoured and are taken
Tablete so okrogle, bež do rjave barve in nedeljive.
voluntarily by most dogs.
Onsior tablete so aromatizirane in jih večino psov prostovoljno vzame.
For the treatment of pain and inflammation of chronic osteoarthritis in dogs.
Za zdravljenje bolečine in vnetja pri kroničnem osteoartritisu pri psih.
Do not use in dogs suffering from stomach ulcer or with liver disease.
Ne uporabite pri psih z razjedo na želodcu ali z obolenji jeter.
Do not use together with other non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, medicines commonly used in the treatment of pain, inflammation and allergies.
Ne uporabite sočasno z drugimi nesteroidnimi antirevmatičnimi zdravili (NSAR) ali kortikosteroidi, zdravili, ki se pogosto uporabljajo pri zdravljenju bolečine, vnetja in alergij.
Do not use in case of hypersensitivity to robenacoxib or to any of the ingredients of the tablets.
Ne uporabite v primeru preobčutljivosti na robenakoksib ali na katerokoli sestavino v tabletah.
Adverse reactions of the digestive tract were reported very commonly, but most cases were mild and recovered without treatment.
Zelo pogosto so bili opisani neželeni učinki v prebavnem traktu, vendar so bili v večini primerov blagi in so se popravili brez zdravljenja.
In dogs treated up to 2 weeks no increases in liver enzyme activities were observed.
Pri psih, zdravljenih do 2 tedna, ni bilo opaziti porasta aktivnosti jetrnih encimov.
However, with long-term treatment increases in liver enzyme activities were common.
Z dolgotrajnim zdravljenjem se je aktivnost jetrnih encimov pogosto zvišala, vendar pa se je z nadaljevanjem zdravljenja stabilizirala oziroma zmanjšala.
In most cases the liver enzyme activities either stabilised or decreased with continued treatment.
Porast aktivnosti jetrnih encimov v povezavi z anoreksijo, apatijo ali bruhanjem je bil manj pogost.
Number of tablets by size Body weight (kg)
Število tablet glede na velikost Telesna masa
A clinical response is normally seen within a week.
Klinični odgovor je normalno viden v enem tednu.
Treatment should be discontinued after 10 days if no clinical improvement is apparent.
V kolikor kliničnega izboljšanja ni po 10 dneh, z zdravljenjem prekinemo.
47 For long-term treatment, once clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoartritis may vary over time.
47 Pri dolgotrajnem zdravljenju lahko po vidnem kliničnem odgovoru odmerek Onsiorja prilagodimo na najnižji učinkovit individualen odmerek, ki ustreza variabilni stopnji bolečine in vnetja v povezavi s kroničnim osteoartritisom.
Regular monitoring should be undertaken by the veterinarian.
Potreben je reden nadzor s strani veterinarja.
Do not administer with food since clinical trials demonstrated better efficacy of robenacoxib when administered without food or at least 30 minutes before or after a meal.
Ne dajajte s hrano, ker so klinične študije dokazale večjo učinkovitost robenakoksiba, če ga damo brez hrane oziroma najmanj 30 minut pred ali po obroku.
Onsior tablets are flavoured and are taken voluntarily by most dogs.
Onsior tablete so aromatizirane in jih večina psov prostovoljno vzame.
Do not use after the expiry date stated on the blister after EXP.
Ne uporabljatjte po datumu izteka roka uporabnosti, navedenega na pretisnem omotu.
The safety of this veterinary medicinal product has not been established in dogs weighing less than 2.5 kg or under 3 months of age.
Varnost tega zdravila ni bila dokazana za pse, lažje od 2, 5 kg telesne mase oziroma mlajše od 3 mesecev.
Thereafter it is recommended to continue regular monitoring, e. g. every 3-6 months.
Pri dolgotrajnem zdravljenju je potrebno izvajati nadzor nad aktivnostjo jetrnih encimov na začetku, npr. po 2, 4 in 8 tednih, v nadaljevanju pa je priporočljiv nadzor vsake 3- 6 mesecev.
Therapy should be discontinued if liver enzyme activities increase markedly or the dog shows symptoms such as anorexia, apathy or vomiting in combination with elevated liver enzymes.
Če se aktivnost jetrnih encimov skokovito poveča oziroma, če pes kaže simptome anoreksije, apatije ali bruhanja v kombinaciji s povečano aktivnostjo jetrnih encimov, z zdravljenjem nemudoma prenehajte.
Use this veterinary medicinal product under strict veterinary monitoring in dogs at risk of stomach ulcer or if the animal previously displayed intolerance to other NSAIDs.
Pri psih s tveganjem za nastanek razjede na želodcu oziroma pri živalih z znano preobčutljivostjo na druge NSAR uporabite to zdravilo za uporabo v veterinarski medicini pod strogim veterinarskim nadzorom.
48 For the person administering the veterinary medicinal product to animals
48 Za osebe, ki dajejo zdravilo živalim
For pregnant women, particularly near term pregnant women, prolonged dermal exposure might increase the risk to the foetus.
Dolgotrajnejši kontakt s kožo nosečnice, zlasti blizu porodnega termina, poveča tveganje za plod.
In artificially induced inflammation in dogs, robenacoxib reduced pain and inflammation with single oral doses ranging from 0.5 to 8 mg/ kg and a rapid onset of action (0.5 h).
Pri umetno induciranih vnetjih pri psih je robenakoksib pričel delovati hitro (0, 5 h) in zmanjšal bolečino in vnetje z enkratnimi peroralnimi odmerki od 0, 5 do 8 mg/ kg.
This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis.
To zdravilo je v kliničnih študijah zmanjšalo šepavost in vnetje pri psih s kroničnim osteoartritisom.
50 PACKAGE LEAFLET FOR:
50 NAVODILO ZA UPORABO ZA:
Kinnoull Road Kingsway West Dundee DD2 3XR United Kingdom
Kinnoull Road Kingsway West Dundee DD2 3XR Velika Britanija
The solution for injection is a clear, colourless to slightly coloured (pink) liquid.
Raztopina za injiciranje je prozorna, brezbarvna do rahlo obarvana (roza) tekočina.
For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery in dogs.
Za zdravljenje bolečine in vnetja v povezavi z ortopedskimi operativnimi posegi ali operativnimi posegi na mehkih tkivih pri psih.
Do not use together with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).
Ne uporabite sočasno s kortikosteroidi ali drugimi nesteroidnimi antirevmatičnimi zdravili (NSAR).
Do not use in case of hypersensitivity to robenacoxib or to any ingredients of the solution.
Ne uporabite v primeru preobčutljivosti na robenakoksib ali na katerokoli sestavino v raztopini.
Adverse reactions of the digestive tract (such as vomiting) were very commonly reported, but most cases were mild and recovered without treatment.
Neželeni učinki na prebavilih (kot je bruhanje) so bili opisani zelo pogosto, vendar so bili v večini primerov blagi in so se popravili brez zdravljenja.
51 Dogs:
Psi:
Adverse reactions of the digestive tract (such as vomiting) were commonly reported but most cases were mild and recovered without treatment.
Neželeni učinki na prebavilih (kot je bruhanje) so bili opisani pogosto, vendar so bili v večini primerov blagi in so se popravili brez zdravljenja.
Cat and dog
Mačka in pes
Administer the solution subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/ kg).
Raztopino dajte subkutano mačkam in psom približno 30 minut pred pričetkom operativnega posega, npr. v času uvajanja splošne anestezije, v odmerku 1 ml na 10 kg telesne mase (2 mg/ kg).
This veterinary medicinal product does not require any special storage conditions.
To zdravilo ne potrebuje posebnih navodil za shranjevanje.
Do not use after the expiry date stated on the label after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki.
After first broaching of the vial, the product may be stored for 28 days.
Po prvem odpiranju viale, se lahko zdravilo hrani 28 dni.
The safety of this veterinary medicinal product has not been established in cats less than 4 months of age and in dogs less than 2 months of age, or in cats or dogs less than 2.5 kg body weight.
Varnost tega zdravila ni bila dokazana za mačke, mlajše od 4 mesecev in za pse, mlajše od 2 mesecev ali za mačke ali pse, lažje od 2, 5 kg telesne mase.
Use this veterinary medicinal product under strict veterinary monitoring in animals at risk of ulceration of the digestive tract, or if the animal previously displayed intolerance to other NSAIDs.
Pri živalih s tveganjem za nastanek razjed v prebavilih oziroma pri živalih z znano preobčutljivostjo na druge NSAR uporabite to zdravilo pod strogim veterinarskim nadzorom.
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively.
Ker lahko anestetiki vplivajo na ledvični pretok, je potrebno ob perioperativni uporabi NSAR premisliti o uporabi parenteralne tekočinske terapije med operativnim posegom za zmanjšanje potencialnih ledvičnih komplikacij.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Zaradi odsotnosti študij o kompatibilnosti, se to zdravilo za ne sme mešati z drugimi zdravili.
For the person administering the veterinary medicinal product to animals
Za osebe, ki dajejo zdravilo živalim
Wash hands and exposed skin immediately after use of the veterinary medicinal product.
Umijte si roke in izpostavljeno kožo takoj po uporabi zdravila.
In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
For pregnant women, particularly near term pregnant women, accidental injection and prolonged dermal exposure might increase the risk to the foetus.
Nenamerno injiciranje in dolgotrajno izpostavljanje kože pri nosečnicah, zlasti blizu porodnega termina, lahko poveča tveganje za plod.
This product reduced in clinical trials pain and inflammation in cats undergoing soft tissue surgery and pain and inflammation in dogs undergoing orthopaedic or soft tissue surgery.
To zdravilo je v kliničnih poskusih zmanjšalo bolečino in vnetje pri mačkah z operativnimi posegi na mehkih tkivih in bolečino ter vnetje pri psih z ortopedskimi operativnimi posegi ali operativnimi posegi na mehkih tkivih.
Tél: +33)-(0)1 55 47 87 47 Ireland Novartis Animal Health UK Ltd.
Tél: +33) - (0) 1 55 47 87 47
Tel: + 386 1 580 2884 Slovenija Novartis Animal Health d. o. o.
Tel: + 386 1 580 2884
54 Latvija Novartis Animal Health d. o. o.
54 Ireland Novartis Animal Health UK Ltd.
United Kingdom Novartis Animal Health UK Ltd.
Slovenija Novartis Animal Health d. o. o.
This document is a summary of the European Public Assessment Report.
Povzetek EPAR za javnost Ta dokument je povzetek Evropskega javnega poročila o oceni zdravila.
Oxyglobin contains bovine haemoglobin glutamer-200 (at a strength of 130 mg/ ml), which belongs to a class of medicines having an oxygen-carrying action.
Zdravilo Oxyglobin vsebuje goveji hemoglobin glutamer- 200 (jakosti 130 mg/ ml), ki spada v razred zdravil z oksifornim učinkom.
Oxyglobin is first warmed to 37°C, then given to the dog as 30 ml per kilogram body weight, administered at a rate of up to 10 ml/ kg per hour.
Zdravilo Oxyglobin morate najprej segreti na 37 °C in ga nato dati psu v odmerku 30 ml na kilogram telesne mase s hitrostjo do 10 ml/ kg na uro.
The most appropriate dose depends on the severity of the anaemia and how long the dog has been anaemic, as well as the desired duration of the medicine ’ s effect.
Najprimernejši odmerek je odvisen od resnosti anemije in trajanja anemičnosti psa, kot tudi želenega trajanja učinkovanja zdravila.
Oxyglobin does not need to be matched to the dog ’ s blood type.
Pri dajanju zdravila Oxyglobin ni treba preverjati krvne skupine psa.
It contains haemoglobin glutamer-200, which is made from haemoglobin (the protein in red blood cells that carries oxygen around the body) extracted from cows’ blood and diluted in a standard solution (Ringer’ s lactate) used to replace blood volume.
Vsebuje hemoglobin glutamer- 200, ki se pridobiva iz hemoglobina (beljakovine v rdečih krvnih celicah, ki po telesu prenaša kisik), pridobljenega iz krvi krav in razredčenega s standardno raztopino (Ringerjev laktat), ki se uporablja za zamenjavo krvne prostornine.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Oxyglobin been studied?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo Oxyglobin izkazalo med študijami?
In the main study in dogs, 95% of the animals treated with Oxyglobin needed no other type of oxygen-carrying treatment after 24 hours, compared with 32% of the dogs that did not receive any treatment.
V glavni študiji pri psih 95% živali, ki so jih zdravili z zdravilom Oxyglobin, po 24 urah ni potrebovalo druge vrste oksifornega zdravljenja medtem ko je druge vrste oksiforno zdravljenje potrebovalo 32% psov, ki niso bili deležni nobenega zdravljenja.
It took longer until additional treatment was needed in dogs treated with Oxyglobin.
Psi, ki so jih zdravili z zdravilom Oxyglobin, so dalj časa zdržali brez potrebe po dodatnem zdravljenju.
A common side effect is ‘ circulatory overload’ (when the blood fluid leaks out of the blood vessels), which causes tachypnea (rapid breathing), dyspnea (shortness of breath), harsh lung sounds and pulmonary oedema (fluid accumulation in the lungs).
Pogost neželen učinek je „ preobremenitev krvnega obtoka “ (kadar tekoči del krvi pronica iz žil), kar povzroči tahipnejo (hitro dihanje), dispnejo (zasopljenost), rezke glasove v pljučih in pljučni edem (zbiranje tekočine v pljučih).
The benefit- risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji najdete v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
©EMEA 2007 Other information about Oxyglobin:
Druge informacije o zdravilu Oxyglobin:
The European Commission granted a marketing authorisation valid throughout the European Union for Oxyglobin to Biopure Netherlands B. V. on 14 July 1999.
Evropska komisija je dovoljenje za promet z zdravilom Oxyglobin, veljavno po vsej Evropski uniji, odobrila družbi Biopure Netherlands B. V. dne 14. julija 1999.
The marketing authorisation was renewed on 14 July 2004.
Dovoljenje za promet z zdravilom je bilo obnovljeno 14. julija 2004.
This summary was last updated on 23 August 2007.
Ta povzetek je bil nazadnje posodobljen 23. avgusta 2007.
Pharmaceutical Form
Farmacevt Način uporabe ska oblika zdravila
Route of administration
Vsebina (koncentracija)
Content (concentration)
Velikost pakiranja
Package size
Ovojnina
EU/ 2/ 99/ 015/ 001 Oxyglobin
EU/ 2/ 99/ 015/ 001 Oxyglobin 130 mg/ ml
130 mg/ ml
Raztopina Psi za infundiranje
Solution for infusion
Uporaba intravenska
Intravenous use
Infuzijske vrečka (poliolefinskima)
Infusion bag 125 ml per bag (polyolefin)
125 ml / vrečka
EU/ 2/ 99/ 015/ 002 Oxyglobin
Navedba smiselno ni potrebna.
Solution for infusion
Raztopina Psi za infundiranje
Dogs
Uporaba intravenska
Infusion bag 60 ml per bag (polyolefin)
60 ml / vrečka
Oxyglobin 130 mg/ ml solution for infusion for dogs.
Oxyglobin 130 mg/ ml, raztopina za infundiranje za pse
Haemoglobin glutamer-200 (bovine) – 130 mg/ ml
Hemoglobin glutamer- 200 (goveji) – 130 mg/ ml
Plasma volume expanders, such as Oxyglobin, are contraindicated in dogs predisposed to circulatory overload with conditions such as oliguria or anuria or advanced cardiac disease (i. e., congestive heart failure) or otherwise severely impaired cardiac function.
Raba ekspanderjev volumna plazme kot je Oxyglobin, je kontraindicirana pri psih, ki so nagnjeni k preveliki obremenitvi krvnega obtoka v stanjih, kot so oligurija ali anurija ali napredujoča bolezen srca (tj. kongestivna srčna odpoved), ali pri kaki drugi hudi okvari srčne funkcije.
Circulatory overload may be controlled by slowing the rate of administration.
Zaradi lastnosti Oxyglobina, ki razširja plazmo, je treba preučiti možnost pojava prevelike obremenitve krvnega obtoka in pljučnega edema, posebno pri dajanju dodatnih intravenskih tekočin, zlasti koloidnih raztopin. preobremenjenosti krvnega obtoka je treba skrbno spremljati ali meriti centralni venski tlak (zvečanje CVP so opazili pri vseh zdravljenih psih, pri katerih so ga merili).
2 Treatment with Oxyglobin results in a mild decrease in PCV (packed cell volume) immediately post infusion.
2 Preveliko obremenitev krvnega obtoka je mogoče nadzorovati z upočasnjenim dajanjem zdravila.
Chemistry:
Biokemija:
The presence of Oxyglobin in serum may interfere with colorometric readings and result in artifactual increases or decreases in the results of serum chemistry tests depending on the dosage administered, the time since infusion, the type of analyzer and the reagents used.
Prisotnost Oxyglobina v serumu lahko vpliva na odčitke kolorimetričnih vrednosti in povzroči umetno zvečanje ali zmanjšanje vrednosti biokemičnih preiskav seruma, odvisno od danih odmerkov, časa, ki je pretekel od infuzije, vrste analizatorja in uporabljenih reagentov.
No interference.
Ni vpliva.
Coagulation:
Koagulacija:
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) can be accurately determined using methods that are mechanical, magnetic, and light scattering.
Protrombinski čas (PT) in aktivirani delni tromboplastinski čas (aPTT) je mogoče natančno določiti z uporabo mehanskih in magnetnih metod in z razprševanjem svetlobe.
Urinalysis:
Preiskava urina:
Sediment examination is accurate.
Preiskava sedimenta je točna.
Dipstick measurements (i. e., pH, glucose, ketones, protein) are inaccurate while gross discolouration of the urine is present.
Meritve z merilnimi trakovi (pH, krvni sladkor, ketoni, beljakovine) niso točne, opazno pa je tudi močno obarvanje urina.
Adverse events related to Oxyglobin and/ or the underlying disease causing anaemia have been observed.
Opazili so neželene pojave v zvezi z Oxyglobinom in/ ali osnovno boleznijo, ki povzroča anemijo.